CJC-1295 + IPA
Batch #010003 · Research use only.
High-purity research peptide for laboratory use
CJC-1295 (No DAC) and Ipamorelin are synthetic peptides widely studied for their synergistic ability to stimulate endogenous growth hormone release through complementary mechanisms. In research settings, this combination is commonly explored for its potential to support muscle recovery, fat metabolism, sleep quality, and tissue repair while maintaining a favorable safety profile in experimental models.
Product overview
CJC-1295 (No DAC) is a growth hormone–releasing hormone (GHRH) analog designed for short-acting, pulsatile GH stimulation, while Ipamorelin is a selective ghrelin receptor agonist that promotes GH release without significantly impacting cortisol or prolactin levels. Together, this research-grade peptide pairing is engineered to mimic natural growth hormone secretion patterns, making it a valuable tool for studying anabolic and regenerative signaling.
Key research features
Growth hormone signaling support:
Studies indicate the CJC-1295 + Ipamorelin combination may significantly enhance endogenous GH pulses by acting on both the GHRH and ghrelin pathways. This dual action is frequently explored in research models examining growth, recovery, and metabolic health.
Recovery and tissue repair research:
This peptide pairing is commonly studied for its potential role in supporting muscle recovery, connective tissue integrity, and cellular repair processes, particularly in high-stress or post-exercise experimental models.
Metabolic and sleep-related pathways:
Research suggests CJC-1295 + Ipamorelin may influence fat metabolism and sleep architecture, making it relevant in studies focused on body composition, circadian biology, and overall metabolic efficiency.
CJC-1295 + Ipamorelin Suggested Use:
Typical Dose: 100–200 mcg of each peptide per injection
Route: Subcutaneous injection
Frequency: 1–2 times daily (morning and/or evening)
Duration: 4–12 weeks, or as recommended by a healthcare professional